Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
ELI LILLY & Co officer Donald A. Zakrowski, SVP, Finance, & CAO, reported selling 2,000 shares of common stock on 2026-08-10 at an average price of $1,185.01 per share in an open-market transaction. After this sale, he held 1,525.89 shares directly and 1,734.73 shares indirectly through a 401(k). The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
A holder of LLY common stock filed to potentially sell 2,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The planned sale has an aggregate market value of approximately $2,371,420.00 as of the filing details provided.
The shares to be sold were acquired on 02/10/2025 from the issuer as Restricted Stock Units and Performance Stock Units, and are now being registered for possible resale.
ELI LILLY & Co executive Anat Hakim, EVP, GC & Secretary, reported a sale of 5,000 shares of common stock on August 7, 2026 at $1,190.00 per share. The shares were held indirectly through her spouse, and she disclaims beneficial ownership except to the extent of her pecuniary interest. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2026. After the sale, 11,875 shares remained held indirectly by her spouse, 22,987.024 shares were held directly, and 15,700 shares were held indirectly through the Anat Hakim SLAT.
Eli Lilly and Company reported strong second-quarter 2026 results, with worldwide revenue of $22.97 billion, up 48% year over year on 60% higher volume, led by diabetes and obesity drugs Mounjaro and Zepbound. Reported EPS rose 26% to $7.94, and non-GAAP EPS increased 33% to $8.38.
Gross margin reached 85.8% of revenue, while net income grew to $7.1 billion despite $2.8 billion of acquired IPR&D and $703 million of acquisition-related charges. Key Products generated $15.7 billion in revenue, and Mounjaro alone delivered $9.9 billion, with Zepbound contributing $4.9 billion.
Full-year 2026 guidance was raised, with revenue now expected between $85 billion and $87 billion and performance margin targeted at 49.0%–50.5%. Non-GAAP EPS guidance was updated to $35.50–$36.50, reflecting strong underlying growth offset by $3.03 per share of acquired IPR&D charges.
ELI LILLY & Co executive Melissa Seymour, EVP Global Quality, exercised 981 restricted stock units into an equal number of common shares on August 1, 2026. To satisfy exercise price or tax obligations, 438.707 shares were withheld at $1,148.8400 per share, and 952 RSUs remain scheduled to vest on August 1, 2027.
Eli Lilly and Company reports ownership of common stock of Ionetix Corp, a Delaware corporation with principal offices in Lansing, Michigan. Eli Lilly beneficially owns 8,411,397 shares of Ionetix common stock, representing 7.98% of the class.
Eli Lilly has sole power to vote and to dispose of all 8,411,397 shares, with no shared voting or dispositive power disclosed. The filing is signed by Christopher Anderson, Vice President – Leader of Corporate Securities and Assistant Corporate Secretary, on July 24, 2026.
Lilly Endowment, Inc., an Indiana not-for-profit private foundation described under Section 501(c)(3) and classified as a private foundation under Section 509(a), reports beneficial ownership of 90,376,978 shares of Eli Lilly and Company common stock as of June 30, 2026.
This position represents 9.6% of Eli Lilly's common stock, based on 941,741,406 shares outstanding as of April 27, 2026, as reported in Eli Lilly's Form 10-Q for the period ended March 31, 2026. Lilly Endowment has sole voting power and sole dispositive power over all 90,376,978 shares, with no shared voting or dispositive power.
ELI LILLY & Co director Gabrielle Sulzberger reported a grant/award acquisition of 4.3232 shares of common stock on July 20, 2026 at $1,146.90 per share. At her election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after her separation from service. Following this award, she directly holds 2,999.7188 shares of Eli Lilly common stock.